<div>
  <ul>
    <li>
      <p>
        Gene editing company Seamless Therapeutics has raised EUR 11.8 million (USD 12.5 million) in a seed financing round co-led by Wellington Partners and Forbion. The raised funds included non-dilutive financing from BMBF GO-Bio, an initiative by the German government.&nbsp;
      </p>
    </li>
    <li>
      <p>
        The Germany-based company follows a gene-editing approach that develops designer recombinases: programmable enzymes that are reportedly capable of editing substantial portions of genes, unlike natural recombinases that work on very specific target sequences. The company plans to use the funding to further develop its technology platform and expand its presence in the EU and US.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20230316005085/en/Seamless-Therapeutics-Launches-with-12.5M-Seed-Financing-to-Advance-Transformative-Gene-Editing-Platform-Based-on-Programmable-Precision-Designer-Recombinases">
      Company press release
    </a>
  </p>
  <p>
    <a href="https://endpts.com/german-biotech-launches-with-seamless-gene-editing-platform-built-on-evolving-enzymes/">
      Endpoints News
    </a>
  </p>
</div>


Human Gene Editing

Seamless Therapeutics raises EUR 11.8 million in seed funding

Chroma Medicine raises USD 135 million in Series B funding

Editas Medicine reports 23% drop in revenue for FY2022

Moderna and ElevateBio’s Life Edit Therapeutics sign gene-editing deal

CRISPR Therapeutics provides an FY2022 update and 2023 outlook

Arbor Biotechnologies and Vertex Pharmaceuticals partner to develop genetic medicines

CRISPR QC raises USD 1.6 million in seed funding

Precision Biosciences provides an FY2022 update and 2023 outlook

Metagenomi raises USD 100 million in Series B extension

Ensoma raises USD 85 million and acquires Twelve Bio

Jalon Therapeutics raises a total funding of USD 2.1 million

First leukemia patient shows no sign of cancer after base editing treatment

Intellia Therapeutics to raise USD 300 million in underwritten public offering

iECURE raises USD 65.1 million in Series A-1

AstraZeneca acquires LogicBio Therapeutics for gene editing technologies

Excision BioTherapeutics secures USD 6.9 million grant to support clinical trials

SparingVision raises EUR 75 million in Series B

All Updates